Statins and risk of type 2 diabetes: mechanism and clinical implications

被引：8
|
作者：
Laakso, Markku [1 ,2 ]
Fernandes Silva, Lilian [1 ]
机构：
[1] Univ Eastern Finland, Inst Clin Med, Internal Med, Kuopio, Finland
[2] Kuopio Univ Hosp, Kuopio, Finland
来源：
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词：
statin; type; 2; diabetes; glucose; insulin secretion; insulin resistance; BETA-CELL FUNCTION; INSULIN-SECRETION; GLYCEMIC CONTROL; FAMILIAL HYPERCHOLESTEROLEMIA; GLUCOSE-TOLERANCE; LOWERING THERAPY; GENETIC-VARIANTS; 000; PARTICIPANTS; CHOLESTEROL; DISEASE;
D O I：
10.3389/fendo.2023.1239335
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Statins are widely used to prevent cardiovascular disease events. Cardiovascular diseases and type 2 diabetes are tightly connected since type 2 diabetes is a major risk factor for cardiovascular diseases. Additionally, cardiovascular diseases often precede the development of type 2 diabetes. These two diseases have common genetic and environmental antecedents. Statins are effective in the lowering of cardiovascular disease events. However, they have also important side effects, including an increased risk of type 2 diabetes. The first study reporting an association of statin treatment with the risk of type 2 diabetes was the WOSCOPS trial (West of Scotland Coronary Prevention Study) in 2001. Other primary and secondary cardiovascular disease prevention studies as well as population-based studies have confirmed original findings. The purpose of our review is to examine and summarize the most important findings of these studies as well as to describe the mechanisms how statins increase the risk of type 2 diabetes.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Statins and diabetes risk: Fact, fiction, and clinical implications
    Rocco, Michael B.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2012, 79 (12) : 883 - 893
  • [2] Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications
    Guber, Kenneth
    Pemmasani, Gayatri
    Malik, Aaqib
    Aronow, Wilbert S.
    Yandrapalli, Srikanth
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2021, 29 (06) : 314 - 322
  • [3] Increased risk of glucose intolerance and type 2 diabetes with statins
    Byrne, Christopher D.
    Wild, Sarah H.
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [4] Statins, Risk of Diabetes, and Implications on Outcomes in the General Population
    Wang, Kang-Ling
    Liu, Chia-Jen
    Chao, Tze-Fan
    Huang, Chi-Ming
    Wu, Cheng-Hsueh
    Chen, Su-Jung
    Chen, Tzeng-Ji
    Lin, Shing-Jong
    Chiang, Chern-En
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (14) : 1231 - 1238
  • [5] Statins for patients with type 2 diabetes
    Pimpinella, G
    Malgarini, RB
    Martini, N
    LANCET, 2004, 364 (9449): : 1933 - 1933
  • [6] Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink
    Ana Filipa Macedo
    Ian Douglas
    Liam Smeeth
    Harriet Forbes
    Shah Ebrahim
    BMC Cardiovascular Disorders, 14
  • [7] Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes
    Chilton, Robert J.
    Dungan, Kathleen M.
    Shubrook, Jay H.
    Umpierrez, Guillermo E.
    PRIMARY CARE DIABETES, 2020, 14 (03) : 193 - 212
  • [8] Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink
    Macedo, Ana Filipa
    Douglas, Ian
    Smeeth, Liam
    Forbes, Harriet
    Ebrahim, Shah
    BMC CARDIOVASCULAR DISORDERS, 2014, 14
  • [9] Economic and clinical implications of statins in cardiovascular risk management
    Barry, M
    PHARMACOECONOMICS, 2003, 21
  • [10] HDL abnormalities in type 2 diabetes: Clinical implications
    Martagon, Alexandro J.
    Zubiran, Rafael
    Gonzalez-Arellanes, Rogelio
    Praget-Bracamontes, Samantha
    Rivera-Alcantara, J. Adrian
    Aguilar-Salinas, Carlos A.
    ATHEROSCLEROSIS, 2024, 394
12345